Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00890968 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis
A Phase 2 study, sponsored by ZARS Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
NCT00890968: Completed Phase 2 study, sponsored by ZARS Pharma.
NCT00890968 is a Phase 2 study that has completed, run by ZARS Pharma. The registered enrollment target is 56 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00890968, a Phase 2 study, has completed, sponsored by ZARS Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Triamcinolone Acetonide (TAC) DuraPeel is safe and effective in the treatment of hand dermatitis.
Interventions
- DRUG Triamcinolone Acetonide (TAC) DuraPeel
- DRUG Placebo DuraPeel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2009-04 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
What the finished NCT00890968 record still lists
NCT00890968 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 2 interventions - of which Triamcinolone Acetonide (TAC) DuraPeel is the first listed.
NCT00890968 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00890968 about?
NCT00890968 is a clinical study titled "Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis". The purpose of this study is to determine whether Triamcinolone Acetonide (TAC) DuraPeel is safe and effective in the treatment of hand dermatitis.
What is the current status of trial NCT00890968?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2009-04. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00890968?
The interventions under investigation include: Triamcinolone Acetonide (TAC) DuraPeel (DRUG), Placebo DuraPeel (DRUG).
Who is sponsoring clinical trial NCT00890968?
This trial is sponsored by ZARS Pharma, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00890968's enrollment target sits among peer trials
56 1146th of 2000 higher than 848 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia